~~Amendments To The Claims:~~

The text of all pending claims (including withdrawn claims) is set forth below. Cancelled and not entered claims are indicated with claim number and status only. The claims as listed below show added text with underlining and deleted text with strikethrough. When strikethrough cannot easily be perceived, or when five or fewer characters are deleted, [[double brackets]] are used to show the deletion. The status of each claim is indicated with one of (original), (currently amended), (cancelled), (withdrawn), (new), (previously presented), or (not entered).

Please AMEND claims 1, 4 and 11, and CANCEL claims 12-14 without prejudice or disclaimer in accordance with the following:

Listing of Claims:

1. (currently amended) A method for improving the effectiveness of an anti-tumor treatment comprising the step of co-administering to a subject in need thereof a pharmaceutical composition comprising as an active ingredient a quinazolinone ~~derivative~~ compound having the ~~general~~ formula I:



wherein: n=1-2

R_1 at each occurrence is independently selected from the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl and lower alkoxy; R_2 is a member of the group consisting of hydroxy, acetoxy and lower alkoxy; R_3 is a member of the group consisting of hydrogen and lower alkenoxy-carbonyl; or pharmaceutically acceptable salt[[s]] thereof, and at least one additional anti tumor treatment; wherein said quinazolinone

~~compound and said at least one additional anti tumor treatment are effective~~ synergistically.

2. (originally presented) The method according to claim 1 wherein the subject is human.

3. (originally presented) The method according to claim 1 wherein the administration of the quinazolinone composition is prior to the administration of the at least one additional anti-tumor treatment.

4. (originally presented) The method according to claim 1 wherein the administration of the quinazolinone composition is substantially at the same time as the administration of the at least one additional anti-tumor treatment.

5. (originally presented) The method according to claim 4 wherein the co-administration is in a single pharmaceutical composition.

6. (originally presented) The method according to claim 4 wherein the co-administration is in separate pharmaceutical compositions.

7. (currently amended) The method according to claim 1 ~~any one of claims 1-4~~ wherein the anti tumor treatment is radiation therapy.

8. (currently amended) The method according to claim 1 ~~any one of claims 1-6~~ wherein the anti tumor treatment is chemotherapy.

9. (currently amended) The method according to claim 1 ~~any one of claims 1-6~~ wherein the anti tumor treatment is selected from the group consisting of immunotherapy, hormonal therapy and genetic therapy.

~~10. (originally presented) The method according to claim 1 wherein the~~ improvement in effectiveness is achieved by enhancement of cellular sensitivity to the anti tumor treatment.

11. (currently amended) The method according to claim 1 ~~any one of claims 1-10~~ wherein the compound of formula I is halofuginone or a pharmaceutically acceptable salt, solvent or hydrate thereof.

12. (originally presented) The method according to claim 8, wherein the additional agent used for chemotherapy is selected from the group consisting of topoisomerase inhibitors, spindle poison vincas: vinblastine, vincristine, vinorelbine (taxol), paclitaxel, docetaxel; alkylating agents: mechlorethamine, chlorambucil, cyclophosphamide, melphalan, ifosfamide; methotrexate; 6-mercaptopurine; 5-fluorouracil, cytarabine, gemcitabin; podophyllotoxins: etoposide, irinotecan, topotecan, dacarbazin; antibiotics: doxorubicin (adriamycin), bleomycin, mitomycin; nitrosoureas: carmustine (BCNU), lomustine, epirubicin, idarubicin, daunorubicin; inorganic ions: cisplatin, carboplatin; interferon, asparaginase; hormones: tamoxifen, leuprolide, flutamide, megestrol acetate.

13. (currently amended) A combined pharmaceutical composition comprising as an active ingredient a quinazolinone ~~derivative~~ compound having the ~~general~~ formula I:



wherein: n=1-2

R_1 at each occurrence is independently selected from the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl and lower alkoxy; R_2 is a member of the group consisting of hydroxy, acetoxy and lower alkoxy; R_3 is a member of the group consisting

~~of hydrogen and lower alkenoxy carbonyl; or pharmaceutically acceptable salt[[s]]~~ thereof, and at least one pharmaceutically acceptable carrier or diluents; further comprising at least one additional anti tumor agent selected from the group consisting of BCNU, radiation, docetaxel and vincristine, or a combination thereof.

14. (currently amended) The pharmaceutical composition according to claims 13 wherein the compound of formula I is halofuginone or a pharmaceutically acceptable salt~~, solvent~~ or hydrate thereof.

15-23. (canceled)

24. (currently amended) The pharmaceutical composition of claim 13 ~~any one of claims 13-16~~ formulated in a form suitable for administration of the composition orally or parenterally.

25. (originally presented) The pharmaceutical composition according to claim 24 wherein the formulation for parenteral administration is selected from a dosage form suitable for intravenous injections, intravenous infusion; intradermal, intralesional, intramuscular, and subcutaneous injections or depots; for administration parenterally by means other than injection, laparascopically, intravesicularly, or intralesionally.

26. (originally presented) The pharmaceutical composition according to claim 24 formulated for oral administration in a form selected from a powder, granules, suspensions or solutions in water or non aqueous media, sachets, capsules or tablets.

27. (currently amended) A method for alleviating or preventing the damage induced by radiation therapy comprising the step of administering to a subject undergoing radiation therapy a pharmaceutical composition comprising as an active ingredient a quinazolinone ~~derivative~~ compound having the formula I:



wherein: n=1-2

R_1 at each occurrence is independently a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl and lower alkoxy; R_2 is a member of the group consisting of hydroxy, acetoxy and lower alkoxy; R_3 is a member of the group consisting of hydrogen and lower alkenoxy-carbonyl; or pharmaceutically acceptable salt[[s]] thereof, further comprising a pharmaceutically acceptable carrier.

28. (currently amended) The method according to claim 27 wherein the compound according to formula I is halofuginone, a pharmaceutically acceptable salt~~, solvent~~ or hydrate thereof.

29. (originally presented) The method according to claim 27 wherein the administration is prior to the administration of radiation therapy.

30. (New) The method of claim 1, wherein said cancer is selected from the group consisting of glioblastoma and pancreatic cancer.